Literature DB >> 15338489

Quality of life and economic burden of illness in very early arthritis. A population based study in southern Sweden.

Maria K Söderlin1, Hannu Kautiainen, Thomas Skogh, Marjatta Leirisalo-Repo.   

Abstract

OBJECTIVE: To measure health related quality of life (HRQOL) in patients with very early arthritis in a population based study in southern Sweden, and to compare HRQOL at baseline between the different diagnostic groups. Further, we investigated whether HRQOL at baseline correlated with the costs the patients incurred during the study.
METHODS: Seventy-one adult patients with arthritis of less than 3 months' duration were referred from primary health care centers to rheumatologists. HRQOL was measured with the Arthritis Impact Measurement Scales (AIMS) and EuroQol at baseline. A comparison of HRQOL measures at baseline and the costs the patients incurred during the study was conducted in 56 of the patients.
RESULTS: Twenty-seven (38%) patients had reactive arthritis (ReA), 17 (24%) undifferentiated arthritis, 15 (21%) rheumatoid arthritis (RA), 4 (6%) psoriatic arthritis, and the rest (11%) other diagnoses. Statistically significant differences were found between the 4 patient groups concerning the AIMS subscales of dexterity, household activity, activities of daily living (ADL) and pain, the patients with RA being most severely affected. There were no statistically significant differences between the 4 diagnosis groups concerning the EuroQol utility and EuroQol visual analog scale (VAS) scores. Of the AIMS subscales, the mobility, physical activity, household activity, ADL, and pain subscales correlated significantly with the incurred costs. Also the EuroQol utility scores and EuroQol VAS scores correlated significantly with the costs. Only the AIMS household activity subscale predicted the costs in the regression analysis.
CONCLUSION: Patients with RA had significantly worse scores in the AIMS dexterity, household activities, ADL, and pain subscales compared to patients with other arthritides very early in the disease. The EuroQol generic quality of life instrument was less sensitive in detecting differences between patients with early arthritis than the disease-specific AIMS instrument. There was a correlation between the costs and the EuroQol utility scores and EuroQol VAS scores during the very first months of the disease, as well as with costs and the AIMS subscales of mobility, physical activity, household activity, ADL, and pain.

Entities:  

Mesh:

Year:  2004        PMID: 15338489

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

2.  Orthopedic surgery core curriculum hip and knee reconstruction.

Authors:  Veronica M R Wadey; William J Maloney; Parvati Dev; Decker Walker
Journal:  Can J Surg       Date:  2008-04       Impact factor: 2.089

3.  Cost-effectiveness of adding magnetic resonance imaging to rheumatoid arthritis management.

Authors:  Lisa G Suter; Liana Fraenkel; R Scott Braithwaite
Journal:  Arch Intern Med       Date:  2011-04-11

Review 4.  Chlamydia-induced ReA: immune imbalances and persistent pathogens.

Authors:  Eric Gracey; Robert D Inman
Journal:  Nat Rev Rheumatol       Date:  2011-11-22       Impact factor: 20.543

5.  Health-related quality of life in patients with common rheumatic diseases referred to a university clinic.

Authors:  Karin Laas; Risto Roine; Pirjo Räsänen; Harri Sintonen; Marjatta Leirisalo-Repo
Journal:  Rheumatol Int       Date:  2008-08-06       Impact factor: 2.631

6.  Swertiamarin ameliorates inflammation and osteoclastogenesis intermediates in IL-1β induced rat fibroblast-like synoviocytes.

Authors:  S Saravanan; V I Hairul Islam; K Thirugnanasambantham; N Pazhanivel; N Raghuraman; M Gabriel Paulraj; S Ignacimuthu
Journal:  Inflamm Res       Date:  2014-02-04       Impact factor: 4.575

7.  Spondyloarthritis is associated with poor function and physical health-related quality of life.

Authors:  Jasvinder A Singh; Vibeke Strand
Journal:  J Rheumatol       Date:  2009-04-15       Impact factor: 4.666

Review 8.  The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life.

Authors:  Roy Fleischmann
Journal:  Open Access Rheumatol       Date:  2009-07-13

9.  Modeled Health Economic Impact of a Hypothetical Certolizumab Pegol Risk-Sharing Scheme for Patients with Moderate-to-Severe Rheumatoid Arthritis in Finland.

Authors:  Erkki Soini; Christian Asseburg; Maarit Taiha; Kari Puolakka; Oana Purcaru; Riitta Luosujärvi
Journal:  Adv Ther       Date:  2017-10-03       Impact factor: 3.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.